Innovative Add-On Treatments for Schizophrenia: May 2018

3.00 CME
180 MINS
$30 FEE
Psych Annals May 2018 Cover


Table of Contents

Supplemental Use of Complementary Alternative Medicine for the Treatment of Schizophrenia

Steven Gabriel, MA; Kristen M. Ward, PharmD; and Vicki L. Ellingrod, PharmD

A Critical Systematic Review of Evidence for Cannabinoids in the Treatment of Schizophrenia

Anoop Sankaranarayanan, MD, MHM, FRANZCP; Helen Wilding, GradDipInfoMgt; Erica Neill, BBSc (Hons), MBSc, PhD; and David Castle, MD, FRCPsych, FRANZCP

Minocycline as an Evidence-Based Adjunct Treatment in Schizophrenia

Deanna L. Kelly, PharmD, BCPP; and Heidi J. Wehring, PharmD, BCPP

Rheumatoid Arthritis Drugs for Schizophrenia?

Peter F. Buckley, MD; and Brian J. Miller, MD, PhD, MPH

Inflammation and Schizophrenia

Jana Caylor Bowcut, MPH; and Mark Weiser, MD

Sponsorship Statement

This CME activity is jointly sponsored by AKH Inc., Advancing Knowledge in Healthcare and Psychiatric Annals.

Support Statement

There is no commercial support for this activity.

Learning Objectives

1. Define the status of clinical research supporting the use of ascorbic acid, polyunsaturated fatty acids, and folate for the treatment of schizophrenia.

2. Analyze the evidence for use of available synthetic cannabinoids in the management of schizophrenia.

3. Define the role of adjunct minocycline in people with schizophrenia.

4. Discuss potential immune-based therapies in the treatment of schizophrenia.

4. Identify the anti-inflammatory hypothesis of schizophrenia.

Faculty names and affiliations:  See authors above

Guest Editors: Peter F. Buckley, MD; and Brian J. Miller, MD, PhD, MPH

Reviewer names:  Andrew A. Nierenberg, MD, Editor and Lenard A. Adler, MD, CME Coordinator, Psychiatric Annals

Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears at the beginning of each CME-accredited article in this issue and also on this page.

Faculty members report the following financial relationships:   Andrew A. Nierenberg, MD, has disclosed the following relevant financial relationships: Appliance Computing Inc. (Mindsite); Astra Zeneca; Brain Cells, Inc.; Brandeis University; Bristol Myers Squibb; Clintara, Dianippon Sumitomo/Sepracor; Eli Lilly and Company; EpiQ, Forest; Johnson and Johnson; Labopharm; Merck; Methylation Science; Novartis; PamLabs; PGx Health; Shire; Schering-Plough; Sunovion; Takeda/Lundbeck Pharmaceuticals; Targacept; Teva: Consultant. APSARD; Belvoir Publishing; Boston Center for the Arts; University of Texas Southwestern Dallas; Hillside Hospital; American Drug Utilization Review; American Society for Clinical Psychopharmacology; Bayamon Region Psychiatric Society; Baystate Medical Center; Canadian Psychiatric Association; Columbia University; Douglas Hospital/McGill University; IMEDEX; International Society for Bipolar Disorders; Israel Society for Biological Psychiatry; John Hopkins University; MJ Consulting; Massachusetts Association of College Counselors; Medscape; MBL Publishing; Physicians Postgraduate Press; Ryan Licht Sang Foundation; Slack Publishing; SUNY Buffalo; University of Florida; University of Miami; University of Wisconsin; University of Pisa; SciMed: Honoraria / travel expenses. Appliance Computing, Inc.; Brain Cells, Inc.: Stock options. AHRQ; Cephalon; Forest; Mylan; NIMH; PamLabs; Pfizer Pharmaceuticals; Takeda; Elan; Shire: Grant / research support.
Lenard A. Adler has disclosed the following relevant financial relationships: research grants paid to New York University (NYU) on Dr. Adler’s behalf from Sunovion Pharmaceuticals, Shire Pharmaceuticals, Lundbeck, Enzymotec, Purdue Pharma; personal fees for consulting or advisory boards from Sunovion Pharmaceuticals, Enzymotec, Shire Pharmaceuticals, the National Football League, Major League Baseball, Shire Pharmaceuticals, Otsuka Pharmaceuticals, Alcobra Pharmaceuticals; and royalty fees from NYU School of Medicine for license of Adult ADHD rating scales and training materials

Authors report the following financial relationships: Steven Gabriel has no relevant financial relationships to disclose. Kristen M. Ward has no relevant financial relationships to disclose. Vicki L. Ellingrod has no relevant financial relationships to disclose. Anoop Sankaranarayanan has no relevant financial relationships to disclose. Helen Wilding has no relevant financial relationships to disclose. Erica Neill has no relevant financial relationships to disclose. David Castle has received grant funding for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, AstraZeneca, and Hospira; travel support and honoraria for talks and consultancy from Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Lundbeck, Janssen Cilag, Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira, and Servier; and is a current Advisory Board Member for Lundbeck, Shire, Pfizer, Servier, and LivaNova. Deanna L. Kelly has received honoraria from Lundbeck and HLS Therapeutics. Heidi J. Wehring has no relevant financial relationships to disclose. Peter F. Buckley receives funding for immunological clinical trials in schizophrenia from the Stanley Medical Research Institute and the Brain and Behavior Research Foundation. Brian J. Miller discloses a salary from Augusta University; grants from Augusta University, the Brain & Behavior Research Foundation, the National Institute of Mental Health, and the Stanley Medical Research Institute; consultant for Psychiatric Times; and contracted research for Alkermes and Sunovion. Jana Caylor Bowcut has no relevant financial relationships to disclose. Mark Weiser has no relevant financial relationships to disclose. Signed disclosures are on file at AKH Inc., Advancing Knowledge in Healthcare.

Accreditation statement(s)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and SLACK Incorporated. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Release date:  May 1, 2018. Expiration Date:  June 1, 2021.

How to Participate

To participate in this CME activity, you must read the learning objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, AKH Inc., Advancing Knowledge in Healthcare will issue an AMA PRA Category 1 Credit(s)™ certificate.

Target Audience

This CME activity is primarily targeted to patient-caring psychiatrists, physicians specializing in psychiatry and others allied to the field. There are no specific background requirements for participants taking this activity. Learning objectives and author disclosures are found at the beginning of each CME article.

Unlabeled and Investigational Usage Statement

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Copyright Statement

Copyright © 2018 by SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without prior written consent of the publisher.